REal-time Data Monitoring for Shared Adaptive, Multi-domain and Personalised Prediction and Decision Making for Long-term Pulmonary Care Ecosystems (RE-SAMPLE)

Pulmonary Disease, Chronic Obstructive Clinical Trial

— RE-SAMPLE  

Official title:

REal-time Data Monitoring for Shared Adaptive, Multi-domain and Personalised Prediction and Decision Making for Long-term Pulmonary Care Ecosystems (RE-SAMPLE)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04955080
• Other study ID #: Grant Agreement No 965315
• Status: Recruiting
• Start date: January 24, 2022
• Est. completion date: September 2024

Study information

• Verified date: March 2023
• Source: Medisch Spectrum Twente
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The main objective of this RE-SAMPLE cohort study is to identify from a real-world data (RWD) set that will be collected, a subset of data that can be potentially used as important predictors and parameters for disease progression of COPD and complex chronic conditions, and multi-morbid exacerbations. The secondary objective is to evaluate the feasibility of RWD collection from a patient's perspective. Study design: This is a prospective observational cohort study to collect RWD in patients with COPD and complex chronic conditions, with a maximum of 38 months of follow-up. Measurements are performed and RWD are collected by using the Healthentia mobile phone application at baseline (e.g. patient characteristics), daily (e.g. symptom diary), during follow-up visits and at deterioration, and from hospital data (e.g. healthcare visits). The choice of parameters and measurement tools that will be collected during the cohort will be updated every three months during the first year of the cohort (via protocol amendments). These updates are based on citizen-design sessions and on new literature insights. Prognostic models will be developed including predictors derived from the RWD collection.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 710
• Est. completion date: September 2024
• Est. primary completion date: September 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

• Clinical diagnosis of COPD according to the GOLD criteria [5] (FEV1 < 80% of the predicted value and FEV1/FVC < 0.70);
• Patients can be included both at stable state and during exacerbation/hospitalization;
• At least one comorbidity:

diabetes mellitus (glucocorticoid-induced, or stable type 1 or 2), chronic heart failure (clinical diagnosis according to the ESC guidelines), ischaemic heart disease (history of myocardial infarction, angina pectoris), active symptoms of anxiety and/or depression (=11 Hospital Anxiety and Depression Scale , and/or anxiety or depression symptoms being treated at the time of inclusion);

• Under treatment at one of the pilot sites (MST, TUK, GEM);
• >40 years of age;
• Smoker or ex-smoker;
• Able to understand, read and write the language spoken in the country of the pilot site.
• Accessibility to internet;
• Written informed consent from the subject prior to participation. Furthermore, 25% of the patients should also have = 2 exacerbations, defined as respiratory problems that required a course of oral corticosteroids / antibiotics in the two years preceding study entry; and/or = 1 hospitalisation for respiratory problems in the two years preceding study entry; and/or modified MRC (mMRC) score of 3 or 4 (COPD patients with these scores have a higher chance of exacerbating).

Exclusion Criteria:

• Serious other diseases with a low survival rate;
• Presence of any other active lung disease (e.g., sarcoidosis);
• Severe psychiatric illness, diagnosed by anamnesis;
• Maintenance therapy with antibiotics
• Patients with cognitive impairment (Mini Mental State Examination (MMSE) < 24)

Related Conditions & MeSH terms

• Comorbidities and Coexisting Conditions
• Exacerbation Copd
• Pulmonary Disease, Chronic Obstructive

Locations

Country	Name	City	State
Netherlands	Medisch Spectrum Twente	Enschede

Sponsors (10)

Lead Sponsor	Collaborator
Medisch Spectrum Twente	Atos IT Solutions and Services Iberia, Deutsches Forschungszentrum fur Kunstliche Intelligenz GMBH, Federation Europeenne des Hopitaux et des Soinds de Sante, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Innovation Sprint, Roessingh Research and Development, Tartu Ülikooli Kliinikum, University of Piraeus, University of Twente

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Predictors for exacerbations of COPD and comorbidities	Prognostic performance of the validated predictive model for COPD and comorbid exacerbations and disease progression from RWD. The measures for progression will be survival, based on all-cause mortality, as well as morbidity. Morbidity is defined as time until first hospitalisation for an acute exacerbation of COPD and CCC, time until first moderate COPD exacerbation, time until first pneumonia, and total number of COPD and CCC exacerbations (extracted from daily symptom diaries) and pneumonia.	Through study completion, an average of 2.5 years.
Secondary	Feasibility of the RWD collection.	This relates to the usability of the application for data collection. The system usability scale will be used as a benchmarking tool that measures the level of usability.	Through study completion, an average of 1 year.
Secondary	Feasibility of the RWD collection.	Assessment of the user experience associated with the data collection. The User Experience Questionnaire will be used to assess the user experience and as a benchmark. Furthermore, patients will be given the opportunity to articulate also in their own words how they experience the RWD collection.	Through study completion, an average of 1 year